Pacific Edge Faces Volume Drop but Advances Push for Medicare Reinstatement of Cxbladder

The latest announcement is out from Pacific Edge Limited ( (PFGTF) ).

Pacific Edge reported its Q3 2026 update highlighting a decline in total laboratory throughput, with overall test volumes down 13.4% and US volumes falling 19.5%, partly offset by a near 10% increase in APAC test volumes driven by commercial demand. Despite the volume pressures and seasonal slowdown, the company emphasized key strategic milestones aimed at restoring and strengthening US Medicare coverage for its Cxbladder tests, including the upcoming Novitas Contractor Advisory Committee meeting, progress in Medicare appeals over denied Cxbladder Triage claims, and new clinical utility evidence from a Kaiser Permanente real-world study accepted for publication. Pacific Edge also underscored the importance of Avalon Healthcare Systems’ endorsement of Cxbladder Triage as meeting coverage criteria for a large insured population, positioning this as influential in policy discussions, and announced boardroom changes with the retirement of Chair Chris Gallaher and the appointment of new Chair Simon Flood as it seeks to secure a more stable reimbursement environment in its key US market.

More about Pacific Edge Limited

Pacific Edge Limited is a global cancer diagnostics company specializing in the development and commercialization of Cxbladder, a suite of non-invasive genomic urine tests used for the detection and risk stratification of urothelial (bladder) cancer in patients with hematuria and those under surveillance for recurrent disease. Headquartered in Dunedin, New Zealand, the company delivers its tests through CLIA-certified laboratories in New Zealand and the United States, with Cxbladder available across the US, Australasia, Israel, and multiple Asian and South American markets, supported by extensive clinical evidence and growing guideline recognition.

See more insights into PFGTF stock on TipRanks’ Stock Analysis page.